Castle Biosciences Inc. President and Chief Executive Officer Derek J. Maetzold filed a Form 4 on November 18, 2026, disclosing the sale of common stock on November 16, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Direct shares sold: Maetzold disposed of 3,904 shares directly at a weighted-average price of $32.92 per share on November 16, 2026.
  • Indirect shares sold via trust: An additional 1,642 shares were sold through The Maetzold Descendants 2020 Trust and 1,396 shares through the Derek Maetzold 2020 Irrevocable Trust, both at the same weighted-average price of $32.92.
  • Price range: According to the filing, the transactions were executed in multiple trades at prices ranging from $32.62 to $33.39, inclusive.
  • 10b5-1 plan: All three sale transactions were made pursuant to a Rule 10b5-1 plan adopted by Maetzold on June 2, 2026.
  • Post-transaction direct ownership: Following the reported transactions, Maetzold's directly held beneficial ownership of common stock stands at 0 shares.
  • Remaining indirect holdings: Maetzold retains indirect beneficial ownership across multiple trusts, including 11,256 shares in each of four Maetzold 2018 Remainder Trusts, 11,963 shares in DJM Grantor Retained Annuity Trust No. 6, 27,862 in No. 7, 40,935 in No. 8, and 23,216 in No. 9.

Maetzold's November 2026 Share Sales Across Direct and Trust Holdings

According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 18, 2026, Derek J. Maetzold, President and Chief Executive Officer of Castle Biosciences Inc. (NASDAQ:CSTL), reported the sale of a combined 6,942 shares of common stock on November 16, 2026. The sales spanned three separate lines of ownership: 3,904 shares held directly, 1,642 shares held indirectly through The Maetzold Descendants 2020 Trust, and 1,396 shares held indirectly through the Derek Maetzold 2020 Irrevocable Trust. All three transactions carried a reported weighted-average sale price of $32.92 per share.

The filing notes that the sales were executed across multiple trades at prices ranging from $32.62 to $33.39 per share, and that Maetzold "undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected." All three transactions bear transaction code "S" and were made pursuant to a Rule 10b5-1 plan that Maetzold adopted on June 2, 2026, according to the filing.

Following the reported sales, Maetzold's directly held beneficial ownership is listed as 0 shares. The filing discloses that Maetzold continues to hold indirect beneficial ownership in a range of family and grantor trusts. These include four Maetzold 2018 Remainder Trusts, each holding 11,256 shares for the benefit of individual children, as well as four DJM Grantor Retained Annuity Trusts holding 11,963, 27,862, 40,935, and 23,216 shares respectively. Maetzold is listed as trustee of the Derek Maetzold 2020 Irrevocable Trust and the four 2018 Remainder Trusts, with his children named as beneficiaries. The Maetzold Descendants 2020 Trust is noted as being managed by Maetzold's spouse as trustee.

What Was Disclosed

The filing reports three sales totaling 6,942 shares of Castle Biosciences common stock on November 16, 2026, at a weighted-average price of $32.92, executed under a Rule 10b5-1 plan adopted June 2, 2026, with ongoing indirect ownership held through multiple family and grantor trusts.